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Background: Sigma2 (σ2) receptors are highly expressed in cancer cell lines and in tumours. Two novel
selective 18F-phthalimido σ2 ligands, 18F-SIG343 and 18F-SIG353, were prepared and characterised for their
potential tumour imaging properties.
Methods: Preparation of 18F-SIG343 and 18F-SIG353 was achieved via nucleophilic substitution of their
respective nitro precursors. In vitro studies including radioreceptor binding assays in the rat brain membrane
and cell uptake studies in the A375 cell line were performed. In vivo studies were carried out in mice bearing
A375 tumours including positron emission tomography (PET) imaging, biodistribution, blocking and metabolite
studies.
Results: In vitro studies showed that SIG343 and SIG353 displayed excellent affinity and selectivity for σ2 receptors
(Ki(σ2) = 8 and 3 nM, σ2:σ1 = 200- and 110-fold, respectively). The σ2 selectivity of 18F-SIG343 was further confirmed by
blocking studies in A375 cells, however, not noted for 18F-SIG353. Biodistribution studies showed that both radiotracers
had similar characteristics including moderately high tumour uptake (4%ID/g to 5%ID/g); low bone uptake (3%ID/g to
4%ID/g); and high tumour-to-muscle uptake ratios (four- to sevenfold) up to 120 min. Although radiotracer uptake in
organs known to express σ receptors was significantly blocked by pre-injection of competing σ ligands, the
blocking effect was not observed in the tumour. PET imaging studies indicated major radioactive localisation
in the chest cavity for both ligands, with approximately 1%ID/g uptake in the tumour at 120 min. Metabolite
studies showed that the original radiotracers remained unchanged 65% to 80% in the tumour up to 120 min.
Conclusions: The lead ligands showed promising in vitro and in vivo characteristics. However, PET imaging
indicated low tumour-to-background ratios. Furthermore, we were unable to demonstrate that uptake in the
A375 tumour was σ2-specific. 18F-SIG343 and 18F-SIG343 do not display ideal properties for imaging the σ2 receptor
in the A375 tumour model. However, since the radiotracers show promising in vitro and in vivo characteristics, longer
scans using appropriate half-life isotopes and alternative tumour models will be carried out in future studies to fully
validate the imaging characteristics of these radiotracers.
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Since its discovery [1], sigma (σ) receptor nomenclature
had undergone considerable changes and has now been
generally accepted as a distinct biochemical entity whose
exact functions still remain elusive. There are at least
two subtypes of σ receptors, σ1 and σ2, which are distin-
guished from each other by their ligand selectivity, mo-
lecular size and postulated pharmacological profile [2-4].
The σ receptors have been characterised in several
species, including human, and have been found unevenly
distributed in the brain [5,6], the endocrine system in-
cluding the liver, spleen, and pancreas [4,7] and in other
peripheral organs such as the testis, ovary, heart and kid-
ney [8-10]. Sigma receptor subtypes were also found to
be both region- and species-specific. For instance, σ1 re-
ceptors were found in higher concentration compared to
σ2 receptors in the brain [5,6] and in the liver of guinea
pig compared to other species [4].
The σ1 gene has been cloned from a variety of mamma-
lian tissue sources [11-15] and shares no sequence hom-
ology to any other cloned mammalian protein. The σ1
receptor was recently identified as a receptor chaperone
in the endoplasmic reticulum (ER) and is involved in ER-
mitochondrial Ca2+ signalling and cell survival [16,17]. To
date, the structure of σ2 receptor is not known, whose
gene has also not been purified, sequenced or cloned. As a
result, the exact role that this receptor has in tumour and
normal cell proliferation is currently unknown. However,
recent data have implicated that σ2 binding sites is likely
to be the progesterone receptor membrane component 1
(PMRMC1) or within PMRMC1 complex which shares
homology with cytochrome b5, a heme-binding protein
that activates cytochrome P450 proteins [18]. This finding
suggested an involvement of σ2 receptors in progesterone
signalling and lipid and drug metabolism [19], and is in
fact in agreement with the hypothesis previously postu-
lated by a number of original reports [12,20-25]. However,
the finding remains to be clarified due to the discrepancies
in molecular weights, opposite responses to PMRCM1
antibody or σ2 receptor antagonists and binding to P450
enzymes of PMRCM1 and σ2 receptors [26].
Overexpression of σ receptors in a variety of human
tumour cells and tissues such as pancreatic, breast, blad-
der, melanoma, colon and brain [27-32] has been re-
ported. Interestingly, σ2 expression was found to be
higher than σ1 expression in certain cell lines [27,33,34].
Several studies have shown that σ2 receptor expression
is a biomarker for the proliferative status of tumour cells
and solid tumours [32,35,36], and are 8 to 10 times over-
expressed in proliferative cells compared to quiescent
cells [32,35]. The PGRMC1 had been reported to be
more abundant in several tumours and/or tumour cell
lines than in healthy control tissues including the lung
[37], breast, colon and thyroid [38] cancer cell lines.Taken collectively, these findings make the σ2 receptor an
attractive molecular target for the development of new ra-
diotracers not only for tumour detection and assessment
of proliferative status, but also for the treatment of cancer
using radiolabelled high-affinity/selectivity σ2 ligands.
Substantial evidence also demonstrates anti-proliferative
and pro-apoptotic activity of σ2 agonists in tumour cells
[32,35]. Sigma ligands with high affinity, but no selectivity
for σ2 receptors, have been reported since the 1990s. Over
the years, the search for σ2 selective ligands has led to the
identification of a number compounds having modest to
high selectivity for σ2 receptors. To date, the majority of σ
radioligands used for positron emission tomography
(PET) and single-photon emission computed tomography
(SPECT) imaging in cancer have either been non-subtype
selective or σ1 selective [39]. Ligands with some selectivity
for σ2 receptors have also been reported; however, they
are presenting a variety of drawbacks (as summarised in
Table 1) including non-specificity (i.e. cross reactivity for
other neuroreceptors), low tumour-to-background con-
trast, short biological half-lives or radiolabelling shortfalls.
18F-labelled radiotracers have been implicated to be super-
ior compared to other PET radionuclide-labelled tracers
in providing higher quality PET images (higher energy),
fewer time constraints (adequate half-life) and in permit-
ting longer scan sessions of higher tumour/normal tissue
ratios [40]. Therefore, the need still remains for the devel-
opment of 18F-labelled σ2 selective radioligands with opti-
mal tumour uptake and rapid washout from non-target
tissues that are suitable for PET or SPECT imaging.
Recently, to address the shortfalls of previously re-
ported σ2 ligands and improve the imaging properties of
new σ2 ligands, our laboratory has developed a new class
of phthalimido σ2 ligands with high affinity and selectiv-
ity for σ2 receptors. The in vitro characterisation and
structure-affinity analysis of these phthalimido com-
pounds indicated that σ2 affinity is significantly en-
hanced by the phthalimido ring. Functionalising with
halogens, such as fluorine, bromine or iodine on the
phthalimido ring, would even further increase this σ2 af-
finity. Using this approach has identified two lead PET
compounds, 18F-SIG343 and 18F-SIG353. In the current
study, our aim was to explore the tumour imaging po-
tential of the two ligands through further in vitro and
in vivo investigation in mice bearing the A375 human
amelanotic melanoma, a cell line that had been reported
to express approximately 100 times of σ2 receptors
higher than its σ1 receptor counterpart.
Methods
General
All reagents and solvents used were obtained from com-
mercially available sources and used with no further puri-
fication. 4-Fluorophthalic anhydride was purchased from
Table 1 Overall review of reported selective σ2 ligands for PET and SPECT
Ligands Radiolabel Ki
a or IC50
b (nM) Comments References
σ1 σ2
125I 554a 1.0a Tumour-to-muscle ratio = 6
(4 h, EMT-6 tumoured mice)
[41]
76Br 5484a 12a Tumour-to-muscle ratio = 2
(2 h, EMT-6 tumoured mice)
[42]
76Br 12900a 8.2a Tumour-to-muscle ratio = 8
(2 h, EMT-6 tumoured mice)
[42]
11C 3078a 10a Tumour-to-muscle ratio = 3
(1 h, EMT-6 tumoured mice)
[43]
18F 330a 6.9a Tumour-to-muscle ratio = 3
(2 h, EMT-6 tumoured mice)
[40]
18F 2150a,c 0.26a,c Tumour-to-muscle ratio = 8
(2 h, EMT-6 tumoured mice)
[40]
125I, 18F 2.8a,d Tumour-to-muscle ratio = 8
(2 h, Line 66 breast tumoured
mice)
[44]
18F 1711a 0.8a Tumour-to-muscle ratio = 2
(2 h, EMT-6 tumoured mice)
[45]
18F 6b 2b Brain-to-muscle ratio = 3
(2 h, naïve mice)
[45]
aKi, determined by ANSTO LifeSciences;
bIC50, determined by Caliper LifeSciences;
csubtype affinity and selectivity performed in EMT-6 cell line; daffinity performed
in line 66 cell line, selectivity not determined.
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anhydride was from Frinton Laboratories Inc. (Hainesport,
NJ, USA). Nuclear magnetic resonance (NMR) spectra
were performed on a Bruker Avance DPX 400 (Bruker
Corporation, Billerica, MA, USA) operating at 400 MHz
for 1H NMR spectra and 100 MHz for 13C NMR spectra.
18F-HF was produced on a GE PET trace via the 18O(p, n)
18F nuclear reaction (RPA Hospital, Camperdown, NSW,
Australia). Haloperidol was obtained from Tocris
Bioscience (Bristol, UK), (+)-pentazocine from Research
Biochemicals Incorporated (Natick, MA, USA) and σ
ligands synthesised in house at LifeSciences, ANSTO
(Lucas Heights, NSW, Australia). For cell uptake studies,
drugs were dissolved in PBS buffer or in saline for injec-
tion for the animal studies, with the help of a few drops of
0.5% acetic acid. Semi-preparative high-performance li-
quid chromatography (HPLC) purification was performed
with a Waters 600 HPLC controller (Waters Company,
Milford, MA, USA) and pump, an in-line UV detector
(Waters 486, 254 nm) and a single sodium diode crystal
flow radioactivity detector (Carrol & Ramsey Associates,
Berkeley, CA, USA) using a Pheonomenex Bondclone
(Lane Cove, New South Wales, Australia) (C18, 10 μm,
300 × 7.8 mm) eluting at 3 mL/min with 30% MeCN/70%
water containing 0.1% TFA.Purity analysis and specific activity
Purity analysis and specific activity of 18F-SIG343 and
18F-SIG353 were performed on a Varian 9002 pump
(Varian Medical Systems, Palo Alto, CA, USA), a linear
UV-VIS detector (λ = 221 nm) in series with an Ortec
ACE Mate Scint 925 γ-detector (Ortec, South Illinois
Ave., Oak Ridge, TN, USA) on a Phenomenex Synergi
Max-RP (C12, 4 μm, 250 × 4.6 mm) eluting at 1 mL/min
with 40% MeCN/60% ammonium acetate (0.1 M) as the
mobile phase. The identity of the labelled compounds
was confirmed by co-injection with the authentic com-
pounds on HPLC. For specific activity calculations, the
radioactivity of the injected product for the radiochem-
ical analysis was measured with a Capintec R15C dose
calibrator (Capintec, Inc., Ramsey, NJ, USA), while the
mass of SIG343 and SIG353 was determined by compar-
ing the area of the UV absorbance peak corresponding
to the carrier product with a calibrated standard curve
relating its mass to UV absorbance.Lipophilicity
The lipophilicity of SIG343 and SIG353 were assessed
using RP-HPLC by determining the logP7.5 value using
literature procedures [46]. Samples, dissolved in metha-
nol, were analysed using a C18 column (RP C18, Xterra,
5 μm, 4.6 × 150 mm) and a mobile phase consisting of
MeOH and phosphate buffer (0.1 M, pH 7.5) compoundswere estimated by a comparison of its retention time to
that of standards of known log P values.
Chemistry
Synthesis of SIG343 and SIG353
2-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)
butyl)-5-fluoroisoindoline-1,3-dione, SIG343 A mix-
ture of 4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl) butan-1-amine (132 mg, 0.5 mmol) [47], 4-fluorophthalic
anhydride (83 mg, 0.5 mmol) and p-xylene (3 mL) was
stirred and gently boiled under a stream of nitrogen. As the
xylene evaporated, more was added to maintain the volume.
Within a few minutes, a viscous pale yellow gum had
formed, but this redissolved slowly, disappearing completely
after 1.25 h to form a pale yellow solution. Heating was con-
tinued for a total of 2 h (approximately 3 mL of additional
xylene required), then the hot solution was treated with
charcoal, filtered through celite and evaporated. The crystal-
line residue was recrystallised from 95% ethanol to give 177
mg (85.9%) of large colourless plates. 1H NMR (CDCl3) δ
1.62 (m, 2H), 1.76 (m, 2H), 2.52 (t, J = 7.5 Hz, 2H),
2.68 (t, J = 5.8 Hz, 2H), 2.79 (t, J = 5.7 Hz, 2H), 3.52 (s, 2H),
3.72 (t, J = 7.0 Hz, 2H), 3.82 (s, 3H), 3.83 (s, 3H), 6.50
(s, 1H), 6.57 (s, 1H), 7.36 (ddd, J = 8.8, 8.2, 2.4 Hz, 1H), 7.50
(dd, J = 7.0, 2.1 Hz, 1H), 7.83 (dd, J = 8.2, 4.5 Hz, 1H). 13C
NMR (CDCl3) δ 24.5, 26.5, 28.6, 38.1, 51.0, 55.7, 55.8, 55.9,
57.6, 109.5, 111.2 (d, J = 24.5 Hz), 111.5, 121.0 (d, J = 23.0
Hz), 125.6 (d, J = 9.6 Hz), 126.1, 126.6, 127.8 (d, J = 2.3 Hz),
135.1 (d, J = 9.2 Hz), 147.2, 147.5, 166.4 (d, J = 230.8 Hz),
167.1 (d, J = 3.0 Hz), 167.8. Anal. C H N (C23H25FN2O4);
theoretical C, 66.98; H, 6.11; N, 6.79; found C, 67.07;
H, 6.16; N, 6.73.
2-(5-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2
(1H)-yl)pentyl)-5-fluoroisoindoline-1,3-dione, SIG353
4-Fluorophthalic anhydride and 5-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)pentan-1-amine were treated
under the same reaction conditions for the synthesis of
SIG343 to give the title compound as colourless crystals.
1H NMR (CDCl3) δ 1.41 (m, 2H) 1.71 (m, 4H), 2.60 (m,
2H), 2.84 (m, 4H), 3.66 (s, 2H), 3.68 (t, J = 7.1 Hz, 2H),
3.82 (s, 3H), 3.83 (s, 3H), 6.51 (s, 1H), 6.57 (s, 1H), 7.36
(ddd, J = 8.8, 8.2, 2.4 Hz, 1H), 7.50 (dd, J = 7.0, 2.4 Hz, 1H),
7.83 (dd, J = 8.2, 4.7 Hz, 1H).
Synthesis of the radiolabelling precursors
2-(4-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)
butyl)-5-nitroisoindoline-1,3-dione (1) 4-Nitrophthalic
anhydride and 4-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)butan-1-amine were treated under the same
reaction conditions for the synthesis of SIG343 to give
the title compound as bright orange crystals. 1H NMR
(CDCl3) δ 1.64 (m, 2H), 1.81 (m, 2H), 2.53 (t, J = 7.5
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3.51 (s, 2H), 3.79 (t, J = 7.2 Hz, 2H), 3.82 (s, 3H), 3.83
(s, 3H), 6.48 (s, 1H), 6.56 (s, 1H), 8.01 (d, J = 7.9 Hz, 1H),
8.58 (dd, J = 7.9, 2.4 Hz, 1H), 8.64 (d, J = 2.4 Hz, 1H). Anal.
C H N (C23H25N3O6); theoretical C, 62.86; H, 5.73; N,
9.56; found C, 63.03; H, 5.64; N, 9.44.
2-(5-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)
pentyl)-5-nitroisoindoline-1,3-dione (2) 4-Nitrophthalic
anhydride and 5-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl) pentan-1-amine were treated under the same
reaction conditions for the synthesis of SIG343 to give
the title compound as bright orange crystals. 1H NMR
(d6-DMSO) δ 1.95 (m, 2H), 2.14 (m, 2H), 2.27 (m, 2H),
2.98 (t, J = 7.0 Hz, 2H), 3.13 (t, J = 5.7 Hz, 2H), 3.22 (t, J =
5.7 Hz, 2H), 3.55 (s, 2H), 3.69 (t, J = 7.0 Hz, 2H), 4.29 (s,
6H), 7.11 (s, 1H), 7.14 (s, 1H), 8.53 (d, J = 7.9 Hz, 1H),
9.04 (d, J = 1.8 Hz, 1H), 9.09 (dd, J = 7.9, 1.8 Hz, 1H).
Radiochemistry
An aqueous 18F-fluoride solution (18F-HF, 6 to 8 GBq)
was added to a 10-mL vial containing anhydrous aceto-
nitrile (1 mL), Kryptofix 2.2.2 (2.0 mg; Sigma-Aldrich
Corporation, St. Louis, MO, USA) and K2CO3 (0.7 mg).
The solvent was evaporated under a stream of nitrogen
at 100°C under vacuum. This azeotropic drying was re-
peated twice by further addition of anhydrous aceto-
nitrile (2 × 1 mL). The nitro precursors (1) or (2) (2 mg)
was dissolved in DMF (0.5 mL) and added to the dried
K222.K2CO3.K
18F complex. The reaction was stirred and
heated at 150°C for 5 min before the reaction mixture
was diluted with mobile phase (500 μL) and purified by
semi-preparative reverse-phase chromatography. The peak
with the retention time corresponding to SIG343 (16 min)
or SIG353 (21 min) was collected and diluted with water
(10 mL) and then trapped on a Waters C18 Light Sep
Pak®. The trapped radiotracer was eluted off the cartridge
with ethanol (1 mL). The ethanol was concentrated in
vacuo and diluted with saline for in vivo studies while it
was diluted with PBS (pH 7.2) for cell studies.
In vitro studies
Radioreceptor binding assays
The test compounds were solubilised in DMSO and di-
luted in 50 mmol/L Tris-HCl (pH 8.0). Membrane ho-
mogenates were prepared from male Sprague-Dawley rat
brains as previously described [48,49]. The binding of σ
ligands to σ1 and σ2 receptors was determined according
to literature methods with minor modification [50]. Briefly,
the percentage of inhibition was determined by incubating,
in triplicate, aliquots of diluted rat brain membrane (300
μg of protein) with 10−11 to 10−5 mol/L concentrations of
the studied drugs in 50 mmol/L Tris-HCl (pH 8.0) with
3H-(+)-pentazocine (3 nmol/L) at 37°C for 2.5 h for σ1receptors or with 3H-DTG (10 nmol/L) and (+)-pentazo-
cine (1 μmol/L) at 25°C for 1.5 h for σ2 receptors. In both
assays, non-specific binding was determined in the pres-
ence of haloperidol (10 μmol/L). After incubation, the re-
action was terminated by rapid filtration using a Brandel
48-well cell harvester (Brandel, Gaithersburg, MD,
USA) over Whatman GF/B glass fibre filters that were
soaked in a solution of 0.5% polyethyleneimine at 4°C for
at least 2 h before use. Filters were washed three times
with 5 mL of ice-cold wash buffer (50 mmol/L Tris HCl,
pH 7.4). The filters were collected and the amount of
bound radioactivity was measured using a β-scintillation
counter (Tri-Carb 2100TR, Packard Instrument Co.,
Downers Grove, IL, USA). The percentage inhibition of
the studied drugs, at concentrations of 10−5 and 10−7 mol/
L, was also determined for the cross activity at a number
of other neuroreceptors (Caliper LifeSciences, MA, USA).
The IC50 values were then converted to apparent Ki values
using the Cheng-Prusoff equation and radioligand Kd
values [51].
Cell culture
A375 (human amelanotic melanoma) cells were purchased
from American Type Culture Collection (Manassas, VA,
USA) and cultured in RPMI-1640 medium (Sigma-Aldrich,
St. Louis, MO, USA) supplemented with 10% foetal calf
serum (Invitrogen, CA, USA) and 2 mM L-glutamine
(Sigma). Cells were maintained in 175 cm2 flasks in at
37°C in 5% CO2:95% atmosphere humidified incubator
and grown to sub-confluent monolayers before being
detached using trypsin for use in animal models.
Cell uptake and inhibition studies
In 24-well culture plates, 2.5 × 105 cells were seeded in
complete medium and left to attach overnight. The fol-
lowing day, the number of cells per well was counted in
triplicate. Before incubation with the radiotracer, the
growth media was removed and the cells were washed
once with warm PBS to remove all traces of growth
media. 18F-SIG343 or 18F-SIG353 was formulated in warm
PBS containing 0.1% Tween-80. Freshly prepared radio-
tracer (0.37 MBq in 500 μL) was added and the cells were
incubated at 37°C for 2, 15, 30, 60 and 120 min. Uptake
was terminated by removing the tracer solution and wash-
ing cells with ice-cold PBS. Subsequently, the cells were
lysed with 500 μL of 0.2 N NaOH. The radioactivity in the
cell lysate was measured with a Wallac 1480 γ-counter
(PerkinElmer, MA, USA). The results were expressed as
percentage of applied dose per 1 × 105 cells. All activities
were corrected for decay. Optimal uptake time will be se-
lected for inhibition cell uptake studies.
The specific uptake of the radiotracers into the cancer cells
was examined in the presence of σ ligands as competitors
(final concentration 5 μM): (+)-pentazocine (σ1), haloperidol
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Cells were prepared as described for uptake studies. Prior to
the addition of the radiotracer, 400 μL of blocking drug (6.25
μmol/L in PBS) or PBS (for controls) was added to the wells.
Freshly prepared radiotracer (0.37 MBq in 100 μL) was
added, and the cells were incubated at 37°C for 15 min as
the optimal time previously determined by the cell uptake
studies. Uptake was terminated as described for uptake stud-
ies. The percentage of uptake in the treatment groups rela-
tive to the control group was determined.
Ethics
Animal experiments were performed according to the
Australian Code of Practice for the Care and Use of Ani-
mals for Scientific Purposes and were approved by the
ANSTO Animal Care and Ethics Committee.
In vivo studies
A375 tumour-bearing mice model
Female Balb/C nude mice aged 5 to 6 weeks old were ob-
tained from the Animal Resource Centre (Perth, Australia).
The animals were kept at a constant temperature of
22°C ± 2°C on a 12/12 h light/dark cycle with lights on
at 09:00 am. Food and water were freely available.
After a week of acclimatisation, mice were injected sub-
cutaneously in the left flank with 1 × 106 A375 human
amelanotic melanoma cells, in 100 μL of Ca2+/Mg2+-free
phosphate buffered saline. The procedure was performed
without anaesthetic. For in vivo studies, A375 tumour-
bearing mice were used 26 days after tumour inoculation.
Biodistribution studies
Tumour-bearing mice were used to examine the tissue
distribution of radioactivity after intravenous injection
into the tail vein of 1 MBq of 18F-SIG343 or 18F-SIG353 in
100 μL of saline. At 15, 30, 60, and 120 min post injection
of the radiotracer, groups of mice (n = 5) were sacrificed
by CO2 administration followed by cervical fracture and
dissection. Selected organs were weighed, and the radio-
activity was measured using a γ-counter. The percentage
of injected dose (%ID) was calculated by comparison with
suitable dilutions of the injected dose. Radioactivity con-
centrations were expressed as percentage of injected dose
per gram of wet tissue (%ID/g), assuming a uniform
density of 1 g/cm3. Data were corrected for the radio-
activity decay and tail injected dose and normalised
for the standard mouse body weight (20 g). The
remaining activity in the carcass was also determined
in order to obtain the total activity in the mouse
(background activity) at each time point.
Blocking studies
Blocking studies were performed to investigate the spe-
cific uptake of the tracer via σ2 receptor mechanism.Haloperidol and the unlabelled compound SIG343 or
SIG353 (1 mg/kg) were administered by intravenous injec-
tion 5 min prior to radiotracer administration. Control
mice received saline only. Five minutes after injection of
the blocking drug, 18F-SIG343 or 18F-SIG353 (1 MBq/100
μL of saline) was injected, and groups of mice (n = 5) were
sacrificed 30 min post injection of the radiotracer. Organs
were processed as described for the biodistribution study.
Radioactivity concentrations in the organs in the treat-
ment groups were compared to that measured in control
mice.Metabolite studies
The amount of intact 18F-SIG343 and 18F-SIG353 in the
plasma, urine, tumour and brain cortex was quantified by
thin layer chromatography (TLC) and radio-HPLC analysis.
Mice were injected with 20 MBq of the radiotracer in 100
μL of saline. Mice were sacrificed 15, 60 and 120 min post
injection of radiotracer. Whole organ samples of brain cor-
tex and tumour samples (10 to 60 mg, minced) were added
to unlabelled SIG343 or SIG353 (5 μL; 1 mg/mL), KF (5 μL;
1 mg/mL), MeCN (0.3 mL) and water (0.2 mL). Samples
were exposed to an ultrasonic probe (Ultrasonic processor,
Misonix Inc., Farmingdale, NY, USA) for 2 min before being
centrifuged (5,000 rpm, 5 min). Plasma (50 μL) or urine
(10 μL) samples were added to unlabelled SIG343 or
SIG353, KF and 0.5 mL MeCN. Plasma samples were
centrifuged (Heraeus Biofuge PrimoR, Thermo Fisher
Scientific, Hudson, NH, USA; 5,000 rpm, 5 min), and
the supernatant was removed and the radioactivity of
the precipitated pellets was measured using a gamma
counter to determine the extraction efficiency. If ne-
cessary, multiple extractions were performed to ensure
maximum recovery of the radioactivity. An appropriate
amount of the supernatant, based on the activity level
(cpm), was collected (approximately 100 μL), diluted
with water (up to 1.5 mL) for HPLC analysis or evapo-
rated to dryness under vacuum for TLC analysis.
The TLC sample was reconstituted in methanol (25 to
50 μL) and mixed before being applied to the concen-
trating zone of the silica TLC plate. In a separate lane,
the corresponding 18F-labelled and 19F-standard was also
spotted. The TLC solvent systems of EtOAc/MeOH
(70:30) were utilised for 18F-SIG343 (rf 0.50) and 18F-
SIG353 (rf 0.55). The UV of the standard was identified
using a UV lamp, while the movement and integration
of the radioactive spots were visualised and measured
using a phosphorimager (BAS 2500 Phosphorimager,
Fujifilm, Tokyo, Japan) with Fujifilm Multigage 3.0 soft-
ware. The intact radiotracer was identified as the radio-
active spot containing the identical rf value to the
corresponding 19F-standard seen under the UV lamp.
The integration of the active spot in relation to all the
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radiotracer.
Radio-HPLC analysis was performed following the
method of Hilton et al. [52]. A pre-column (Waters Oasis
HLB, 25 μm, 20 × 3.9 mm) and a reversed phase HPLC
column (Phenomenex Bondclone C18, 10 μm, 250 × 4.6
mm or Phenomenex Synergi Max-RP 80A C18, 4 μm,
250 × 4.6 mm) in series, with a switching valve between
columns was utilised. The pre-column was washed with
1% acetonitrile in water for 3 min at 1.5 mL/min and
then the solvent direction was switched to include the
HPLC column. Both columns in series were then eluted
over 10 min. The radioactivity peak corresponding to the
authentic radiotracer was compared to the total activity
registered in the radiochromatogram to give the fraction
of unchanged radiotracer in the sample.PET/CT imaging studies
The mouse was anaesthetised via inhalant isoflurane
(Forthane, Abbott Laboratories, IL, USA) (5% induction,
1% to 3% maintenance in 200 mL/min oxygen). Respir-
ation and heart rates of the animal were monitored
(BioVet; m2m Imaging Corp, Cleveland, OH, USA) during
the entire scanning period. The core body temperature of
the animals was maintained via a temperature-controlled
heating pad. The mouse was injected intravenously with
4.6 to 16.7 MBq of 18F-SIG343 or 18F-SIG353, with a con-
stant mass of the unlabelled compounds of 0.06 nmol in
100 μL of saline (n = 3). A 120-min PET scan was per-
formed on an Inveon multimodality positron emission
tomography-computed tomography (PET/CT) system
(Siemens Medical Solutions, Knoxville, TN, USA) followed
by a 10-min CT scan on each subject for anatomical in-
formation. Image acquisition commenced simultaneously
with radiotracer injection. The data was histogrammed
into 25 consecutive frames, and activity volumes were
reconstructed with an iterative reconstruction (OSEM/
MAP) including attenuation and scatter correction, achiev-
ing a reconstructed spatial resolution of 1.5 mm [53].
Briefly, each individual PET scan was co-registered to its
respective CT (automatic and visual quality control)
(Anatomist/Brainvisa, version 3.1.4). Regional activity
data (Bq/cc) were extracted from nine selected volumes/
regions of interest (VOIs/ROIs) where σ receptor dis-
tribution was reported and the tail and expressed
as percentage of injected dose per cubic centimetres
(%ID/cc).Data and statistical analyses
Significant outliers were identified by Grubb tests and
removed from the raw data set. Subsequently, data were
analysed using the GraphPad Prism 5.04 (GraphPad
Software Inc., San Diego, CA, USA) statistical packagesoftware. Significance was set at P ≤ 0.05 for all statistical
analyses.
In the cell uptake blocking studies, separate one-way ANO-
VAs [drug treatment as a factor (control, (+)-pentazocine,
haloperidol and unlabelled SIG343 or SIG353)], followed
by Bonferroni's post hoc tests were performed to statisti-
cally determine the significant changes in the uptake per-
centage of the radiotracers into the cells compared to
controls.
Selected tumour-to-organ (tumour-to-blood and tumour-
to-muscle) uptake ratios (TORs), were calculated by dividing
the tumour radioactivity concentration (%ID/g) by the
radioactivity concentration in the respective organ at
time t. Comparisons of organ radioactivity concentra-
tions (%ID/g) and TORs in the biodistribution studies
or %ID/cc in PET imaging studies between the two ra-
diotracers were performed using separate unpaired,
two-tailed Student's t tests, matched organs and time
points.
Meanwhile, for the blocking studies, separate within-group
two-way ANOVAs [drug treatment (control, haloperidol and
unlabelled SIG343 or SIG353) × regions] followed by Bon-
ferroni's post hoc tests were performed for each radio-
tracer to determine any statistically significant changes in
the uptake (%ID/g) amongst selected ROIs compared to
the control.
Results
Chemistry
The synthesis of SIG343 and SIG353 and their respect-
ive nitro-radiolabelling precursor was via a condensa-
tion of the appropriate phthalic anhydride with either
4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)butan-
1-amine for the SIG343 pair or 5-(6,7-dimethoxy-3,4-
dihydroisoquinolin-2(1H)-yl)pentan-1-amine for the SIG353
pair (Scheme 1). Recrystallisation of these compounds
from aqueous ethanol gave these compounds as crystals
in greater than 80% yield. Interestingly, SIG343 and
SIG353 were stable colourless crystals, whereas the nitro
equivalents of these compounds were both initially bright
orange crystals that darkened to brown crystals over a
week on the bench. Stability, as indicated by the bright or-
ange state of the nitro precursors, was maintained over a
year by storing them under nitrogen in a dark vial in the
freezer.
Radiochemistry
Radiotracers 18F-SIG343 and 18F-SIG353 were synthesised
by aromatic nucleophilic substitution of their respective
nitro precursors, (1) and (2) (Scheme 2), using potassium
carbonate and Kryptofix 222 in DMF at 140°C for 5 min.
The isolated collected radiolabelled yields were similar for
each radiotracer, 18 ± 5% (n = 13) and 18 ± 7% (n = 13)
(non-decay corrected) for 18F-SIG343 and 18F-SIG353,
H2N N
n
OMe
OMeO
O
O
X
N N
n
OMe
OMe
O
O
X
SIG343   X = F, n = 4
SIG353   X = F, n = 5
SIG 343 radiolabelling precursor (1)  X = NO2, n = 4
SIG 353 radiolabelling precursor (2)  X = NO2, n = 5
Xylene
140 oC
2 h
Scheme 1 Synthesis of sigma phthalimide derivatives SIG343,
SIG353 and their radiolabelling precursors.
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an important parameter that affected the yield. Levels of
potassium carbonate above 1 mg generally resulted in
lower yields possibly by inducing hydroxide formation
from trace amounts of water in the reaction, with subse-
quent ring opening of the phthalimido ring or acting as a
competitor of the fluoride.
The radiochemical purity of both radiotracers was
greater than 97% over 3 h in a saline solution, while spe-
cific activity was greater than 82 GBq/μmol at time of
injection for all studies.
In vitro studies
Radioreceptor binding assays
SIG343 and SIG353 were evaluated using competitive
inhibition experiments to determine their binding affin-
ity (Ki) to the σ1 and σ2 receptors and a number of other
neuroreceptors for their selectivity. The radioreceptor
binding studies showed high affinity and high selectivity
for σ2 receptors, with 200- and 110-fold selectivity for σ2N
O
O
N
OMe
OMe
O2N n
n = 4  (1)
n = 5  (2)
H18F
K22
K2C
DMF
150o
5 mi
Scheme 2 Radiosynthesis of 18F-SIG343 and 18F-SIG353.receptors compared to σ1, for SIG343 and SIG353, re-
spectively. The compounds did not show any cross re-
activity for the other neuroreceptors examined (IC50 >
10,000 nM). The Ki or IC50 values and logP values are
shown in Table 2.
Cell uptake and inhibition studies
The uptake of 18F-SIG343 and 18F-SIG353 in the A375
amelanotic human cell lines was explored over 120 min.
Uptake in A375 cells for both radiotracers was found to
be rapid (approximately 2%, after 2 min), peaked at 3%
to 3.5% between 15 and 60 min for 18F-SIG353 and plat-
eaued at 2% for 18F-SIG343 for the same period. Uptake
slightly declined after 60 min to 1.6% to 2.3% for 18F-
SIG343 and 18F-SIG353, respectively (Figure 1a). In par-
allel studies, the specific cell uptake due to σ receptor
binding was verified by the presence of a variety of σ
ligands including (+)-pentazocine (σ1), haloperidol
(non-selective σ1/σ2) and unlabelled SIG343 and SIG353
(σ2). One-way analysis of variance (ANOVA) analysis
(treatment as a factor) indicated an overall significant vari-
ation in the cell uptake values amongst all treatment groups
for 18F-SIG343 (F3,8 = 2.78, P < 0.01). Bonferroni’s post hoc
tests revealed the cell uptake of 18F-SIG343 was significantly
reduced by haloperidol (−72%, P < 0.05) and unlabelled
SIG343 (−69%, P < 0.05), whereas (+)-pentazocine produced
no significant blocking effect on 18F-SIG343 cell uptake
compared to the controls (Figure 1b). In contrast, the uptake
of 18F-SIG353 into A375 cells was not significantly reduced
by any of the competing σ ligands (F3,8 = 2.59, P = 0.0579)
(Figure 1c) using the same statistical assessments.
In vivo studies
Biodistribution studies
The tissue distribution of radioactivity in Balb/C nude
mice bearing A375 tumours following intravenous ad-
ministration of 18F-SIG343 and 18F-SIG353 is summarised
in Table 3. In general, both radiotracers exhibited similar
biodistribution profiles. The highest initial uptake was ob-
served in the liver, kidneys, lungs and pancreas for both
radiotracers. In organs that are known to express the σ2
receptors [13,15,54,55], the clearance of the radiotracer
was only observed in the brain, lungs, kidneys, spleen
and heart. Moderately high uptake values in theN
O
O
N
n
OMe
OMe18F
n = 4  [18F]SIG343
n = 5  [18F]SIG353
2
O3
C
ns
Table 2 In vitro characteristics of SIG343 and SIG353
Parameters Compound
SIG343 SIG353
Affinity (nM)
σ1a 1,600 266
σ2a 8 2.4
Opioid, non-selectiveb >104 >104
Dopamine, non-selectiveb >104 >104
Serotonin, non-selectiveb >104 >104
CB1, non-selective
b >104 >104
Muscarinic, non-selectiveb >104 >104
Selectivity
σ2:σ1 200 110
Lipophilicity
LogPb 3.11 ± 0.08 3.47 ± 0.09
a Ki, determined by ANSTO LifeSciences;
bIC50, determined by
Caliper LifeSciences.
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tracers (Figure 2a,b). Radioactivity accumulated in the
tumour and ovaries over time, while uptake in the liver
and pancreas continued to increase for the duration of the
study resulting in the lack of clearance of the radiotracers.
Uptake in the bone was measurable and remained stable
over time, suggesting no significant in vivo de-fluorination
and subsequent fluoride bone uptake.
Despite the similarities, the two radioligands exhibited
some differences in the extent and the rate of uptake.
For instance, a significantly higher uptake of 18F-SIG343Figure 1 Cell uptake and inhibition studies. (a) Cell uptake studies over 120
(b) and 18F-SIG353 (c) in the presence of competing σ ligands: (+)-pentazocine, h
percentage of applied dose per 1 × 105 of A375 amelanotic human cells with de
(one-way ANOVAs with treatment as a factor, followed by Bonferroni's post hoc tcompared to that of 18F-SIG353 was observed in the
brain, spleen, heart, kidney, lung, and tumour between
30 and 60 min (0.0001 < Ps < 0.05). In contrast, the
uptake of 18F-SIG353 was significantly higher than
18F-SIG343 in the liver and pancreas for the same period.
At 120 min, the uptake in the lungs, kidneys, tumour and
heart was not different between the two radiotracers. The
uptake in the ovaries was not different between the two
radiotracers at any time point. In the brain, clearance was
found to be more rapid for 18F-SIG353, whereas the lung
clearance was faster for 18F-SIG343.
Tumour-to-blood and tumour-to-muscle uptake ratios
were derived from the biodistribution data. Both 18F-
SIG343 and 18F-SIG353 showed similar tumour-to-blood
uptake ratios (eight- to ninefold at 120 min), whereas
18F-SIG353 had significantly higher tumour-to-muscle
uptake ratios compared to that of 18F-SIG343 at any
time point (0.0001 < Ps <0.05) (Figure 3a). The highest
tumour-to-muscle uptake ratio was observed at 120 min
for 18F-SIG353 (sevenfold) (Figure 3b).
Blocking studies
The degree of in vivo specific binding of 18F-SIG343 and
18F-SIG353 due to σ2 receptors was examined using blocking
studies performed in the same animal model. The blocking
effect on radiotracer uptake following pre-administration of
haloperidol (non-selective σ2) and unlabelled SIG343 or
SIG353 (σ2) as competitors was observed in various tissues
at 30-min post injection of the radiotracer.
Nine organs and tissues that are known to have σ re-
ceptors that are widely distributed including the brain,min of 18F-SIG343 and 18F-SIG343. Cell uptake inhibition studies of 18F-SIG343
aloperidol, unlabelled SIG343 or SIG353 (5 μM). Results were expressed as
cay correction (means ± SD, n= 3). *P <0.05 drug treatment versus control
ests).
Table 3 Biodistribution of 18F-SIG343 and 18F-SIG353 in representative tissues (decay corrected)
Compound Time
(min)
Brain Liver Spleen Kidneys Femur Lungs Heart Blood Pancreas Ovaries Tumour
18F-SIG343 15 9.6 ± 0.2*** 16.0 ± 0.9** 14.6 ± 1.2 26.1 ± 0.6 4.5 ± 0.4 30.3 ± 1.2*** 5.5 ± 0.4 0.9 ± 0.1 42.9 ± 2.8* 10.8 ± 1.8 3.1 ± 0.5
30 8.8 ± 0.6*** 21.9 ± 0.8*** 15.2 ± 1.1* 19.8 ± 0.9*** 4.3 ± 0.2 17.4 ± 0.7*** 3.5 ± 0.2** 0.7 ± 0.04 50.2 ± 2.0*** 14.0 ± 2.2 3.0 ± 0.1*
60 7.1 ± 0.4*** 15.2 ± 1.1*** 12.8 ± 0.9*** 12.0 ± 0.6** 3.8 ± 0.1 9.9 ± 0.3*** 1.9 ± 0.04** 0.6 ± 0.1 64.4 ± 3.5*** 13.5 ± 2.2 3.5 ± 0.3*
120 5.2 ± 0.7*** 19.8 ± 0.9* 8.5 ± 0.2*** 7.5 ± 0.4 3.2 ± 0.1 5.0 ± 0.3 1.1 ± 0.1 0.4 ± 0.01 61.7 ± 3.4*** 11.5 ± 1.4 3.9 ± 0.2
18F-SIG353 15 4.4 ± 0.2 23.5 ± 2.0 15.7 ± 1.1 23.4 ± 2.0 5.3 ± 0.3 17.4 ± 0.5 4.5 ± 0.2 1.2 ± 0.03 56.4 ± 4.7 10.0 ± 0.9 3.8 ± 0.3
30 2.3 ± 0.1 33.0 ± 1.8 12.0 ± 0.6 13.3 ± 0.8 4.7 ± 0.2 8.6 ± 0.4 2.5 ± 0.1 1.0 ± 0.1 72.8 ± 2.4 11.8 ± 1.5 3.8 ± 0.3
60 1.3 ± 0.01 32.6 ± 1.0 7.7 ± 0.4 8.7 ± 0.3 3.8 ± 0.2 6.1 ± 0.1 1.7 ± 0.02 0.7 ± 0.02 94.3 ± 4.2 9.6 ± 1.5 4.6 ± 0.2
120 0.8 ± 0.02 24.1 ± 1.4 5.5 ± 0.2 7.1 ± 0.2 3.9 ± 0.1 4.7 ± 0.2 1.3 ± 0.1 0.7 ± 0.03 119.2 ± 1.6 12.2 ± 3.1 4.8 ± 0.4
Data are presented as the means of percentage of injected dose per g of tissue (%ID/g± SEM, n=5). Comparisons of 18F-SIG343 vs. 18F-SIG353, unpaired two-tailed Student's
t test, matched organ and time point. SEM scanning electron microscopy *0.01 < P<0.05 (significant); **0.001 < P<0.01 (very significant); ***P< 0.001 (extremely significant).
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tumour were included in statistical analyses. Separate
within two-way ANOVAs (drug treatment × regions)
examining the blocking effect of pre-administration of
competing σ ligands on 18F-SIG343 organ distribution.
Significant main effects of treatment (F2,107 = 11.38, P <
0.0001), regions (F8,107 = 1,249, P < 0.0001) and the signifi-
cant interaction between the two factors (F16,107 = 57.38,
P < 0.0001) were also noted. Similar significant blocking
was found in almost organs expressing σ receptor in both
haloperidol- and unlabelled SIG343-treated groups includ-
ing brain (↓78% to 79%, Ps < 0.001), liver (↓20% to 37%,
Ps < 0.001), spleen (↓45% to 52%, Ps < 0.001), and lungs
(↓53% to 60%, Ps < 0.001), respectively (Figure 4a).
On the other hand, in similarly designed analysis, separ-
ate 2-way ANOVAs were also carried out to evaluate the
blocking effect of competing σ ligands on 18F-SIG353 re-
gional distribution. Significant main effects of treatment
(F2,107 = 7.38, P < 0.001), regions (F8,107 = 691.5, P < 0.0001)
and significant interaction between the two variables
(F16,107 = 11.8, P < 0.0001) were observed. Bonferroni post
hoc revealed only significant blocking occurred in the liver
(↓38% to 41%, Ps < 0.001) for both haloperidol and un-
labelled SIG353 treatment groups, respectively. UptakeFigure 2 Comparisons of the uptakes in tumour (a) and tumour-to-back
presented as %ID/g in the tumour and the uptake in the tumour compared t
uptake ratios) at 15, 30, 60 and 120 min. Data are derived from the biod
n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 treatment versus control (unpairof 18F-SIG353, however, increased in the pancreas for
the unlabelled SIG353-treated group (↑37%, P < 0.001)
(Figure 4b).
Metabolite studies
The stability of the 18F-SIG343 and 18F-SIG353 in vivo was
studied over 120 min, after i.v. injection in tumour, brain
cortex, plasma and urine samples. The results shown in
Table 4 suggest that both radiotracers have similar stabilities
in vivo. The determination of the unchanged radiotracer
was carried out by radio-HPLC and radio-TLC. Both analyt-
ical methods generated results in concordance with each
other presenting a similar trend of in vivo stability.
Following ultrasonic disruption and centrifugation of
tissue, at least 81% of radioactivity from the tumour
and brain cortex was recovered in the supernatant
from samples collected at 15, 60 and 120 min. How-
ever, 18F-SIG353 radioactivity collected from brain at
15 and 60 min was too low for detection radio-HPLC
so only the radio-TLC data are included for this tissue.
Radioactivity collected from brain at 120 min was too
low to detect by radio-HPLC and radio-TLC, therefore
this sample was not analysed. More than 80% of recov-
ered radioactivity was intact 18F-SIG343 in the tumourground uptake ratios (b) of 18F-SIG343 and 18F-SIG353. Results were
o the residual activity remained in the body (tumour-to-background
istribution studies in A373 tumour-bearing mice (means ± SEM,
ed, two-tailed Student's t test).
a*
**
***
**
b
Figure 3 Comparisons of the tumour-to-blood (a) and tumour-to-muscle (b) uptake ratios of 18F-SIG343 and 18F-SIG353. Results were
presented as the ratios of the radioconcentration (%ID/g) in the tumour and in the blood or muscle at 15, 30, 60 and 120 min. Data are derived
from the biodistribution studies in A373 tumour-bearing mice (means ± SEM, n = 5). *P < 0.05, **P < 0.01, ***P < 0.001 treatment versus control
(unpaired, two-tailed Student's t test).
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18F-SIG353 was not as stable in the tumour with intact
radiotracer reduced to 65% at 120 min. However, there
was no significant decrease in the percentage of un-
changed radiotracers found (less than 10%) in the
above-mentioned organs, at 120 min post injection.
In plasma, rapid decrease of unchanged radiotracers
was observed; the percentage of unchanged 18F-SIG343
and 18F-SIG353 was reduced from 60% at 15 min to 17%
at 120 min. In urine, unchanged 18F-SIG343 was rapidly
reduced to 13% at 15 min while only 5% of radioactivity
was intact 18F-SIG353 at 15 min.PET studies
Results from the PET imaging studies showed high uptake
in the chest cavity for both radiotracers, with continuous ac-
cumulation in the liver. Low uptakes were observed in the
tumour, with 18F-SIG353 having higher uptake compared to
18F-SIG343, (P < 0.05) resulting low tumour-to-background
contrast. Time-activity curves of 18F-SIG343 and 18F-
SIG353 of selected organs are presented in Figure 5a,b.a
**
**
**
**
Figure 4 Blocking studies of 18F-SIG343 and 18F-SIG353. Blocking studi
σ2 ligands: haloperidol, unlabelled SIG343 or SIG353 (1 mg/kg), respectively
organs in the treatment group compared to controls (means ± SEM, n = 5).
ANOVAs (treatment × regions), followed by Bonferroni's post hoc tests).Discussion
In the current study, radioreceptor binding assays identi-
fied two lead σ2 ligands, SIG343 and SIG353, from a
series of phthalimide derivatives that have high affinity
and are highly selective for σ2 receptors. From literature,
it is interesting to note that the structure designed for
the σ receptor also shows affinity for the related dopa-
mine receptors [56,57]. However, small structural differ-
ences can greatly influence a compounds affinity and
selectivity for any of the receptors. As a result, our
in vitro data indicated that the compounds have no af-
finity for dopamine receptors.
The potential of these tracers as imaging agents for
identification of σ2 receptor localisation in vivo, particu-
larly in tumours, was explored. A number of cancer cell
lines that express various concentrations of σ receptors
have been described; however, the level of expression of
the two σ subtypes was often not reported [39]. Amongst
these cell lines, MDA-MB-231 and PC-3 cell lines were
reported to express 16% and 33% of σ2 receptors, respect-
ively [27]. The A375 human amelanotic cell line was re-
ported to express high concentration of σ2 receptors,**
*
b
es of 18F-SIG343 (a) and 18F-SIG353 (b) in the presence of competing
. Results were expressed as radioconcentration of the tracers in the
*P <0.001 drug treatment versus control (within-group two-way
Table 4 Percentage of the unchanged form in organs and
associated sample recovery of 18F-SIG343 and 18F-SIG353
Compound Time
(min)
Unchanged form (%)a [sample recovery (%)]b
Tumour Cortex Plasma Urine
18F-SIG343 15 79 ± 4.6 (86) 87 ± 3.2 (92) 49 ± 7.5
(89 ± 14.4)
13 ± 1.2
60 85 ± 3.1 (90) 83 ± 0.8 (88) 23 ± 3.8
(86 ± 16.4)
15 ± 4.3
120 80 ± 5.0 (86) 86 ± 1.0 (90) 16 ± 2.8
(91 ± 9.0)
11 ± 5.4
18F-SIG353 15 81 ± 4.5 (86) 85 (91) 60 ± 3.0
(92 ± 6.8)
5 ± 1.3
60 85 ± 2.4 (90) 87 (93) 27 ± 5.1
(88 ± 10.7)
4 ± 0.4
120 65 ± 8.9 (81) IR 17 ± 2.9
(94 ± 5.3)
5 ± 1.2
aMeans ± SD (n =3); bthe recovery of the radioactivity. IR insufficient
radioactivity for analysis.
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type [27]. The relationship of σ2 receptors and cellular
proliferation was explored and demonstrated that prolifer-
ative cells have ten times more σ2 receptors than quies-
cent cells, although full down-regulation of the σ2
receptor was reached only several (>3) days after the cells
had become quiescent [32]. Thus, the half-life of the σ2 re-
ceptor appeared to be rather long (>12 h) [39]. In our
study we seeded the cell cultures overnight after the cells
had reached 80% confluence (i.e. proliferative phase) to
ensure the cells were expressing the maximum amount of
σ2 receptors in the cells, also to optimise signal-to-noise
ratio in cell uptake studies. The results from the cell up-
take inhibition studies are in agreement with the in vitro
receptor binding data confirming that SIG343 has a higher
selectivity for σ2 receptors, compared to SIG353.
Biodistribution studies in tumoured mice indicated
that statistically significant uptake of 18F-SIG343 andFigure 5 Time-activity curves of 18F-SIG343 (a) and 18F-SIG353 (b) in s
(min) (means ± SD, n = 3). Mice were injected intravenously with 4.6-16.7 M
unlabelled compound of 0.06 nmol/100 μL of saline. A 120-min PET scan w
scan on each subject for anatomical information.18F-SIG353 were retained in the organs known to ex-
press high densities of σ receptors such as the brain,
liver, kidneys, lungs, pancreas and ovaries. As the uptake
of the radiotracers in the liver and pancreas was still in-
creasing, it is possible that the terminal half-lives of
these ligands are longer than 120 min which is beyond
the last time point of the study. Lack of clearance of the
tracers observed at 120 min may be attributable to either
continuing accumulation of the radiotracer and/or its
radioactive metabolite in the liver and pancreas.
Despite some similarities in distribution profiles and
clearance in the organs, the two radiotracers exhibited
some differences in the extent and the rate of uptake.
For instance, a significantly higher uptake of 18F-SIG343
compared to that of 18F-SIG353 was observed in the
brain and the lung. However, the brain clearance was
more rapid for 18F-SIG353, and the lung clearance was
faster for 18F-SIG343. High to moderately high brain up-
take of the radiotracers together with their appropriate
lipophilicity indicated that the radiotracers are also suit-
able as imaging agent for receptors in the brain.
Moderately high and prolonged tumour uptake, 3% to
4% and 4% to 5% for 18F-SIG343 and 18F-SIG353, re-
spectively, throughout the study and up to 120 min,
showed promising tumour imaging potential for these
radiotracers. Both radiotracers showed similar trends of
increasing tumour-to-blood and tumour-to-muscle up-
take ratios over time. Selective σ2
18F-radioligands for
PET imaging from the literature were reported to have
tumour-to-muscle ratios ranging from 2 to 8 at 120 min
in various tumoured mouse models (Table 1). Tumour-
to-muscle uptake ratios of 18F-SIG343 and 18F-SIG353
are 4 and 7 at 120 min respectively, which are compar-
able to those reported. Similarly, the tumour-to-blood
uptake ratios were high at 8 to 9 for both radiotracers as
a result of the increasing radiotracer uptake in tumourelected organs. Results were expressed as Activity (%ID/cc) over Time
Bq of 18F-SIG343 or 18F-SIG353, with a constant tracer mass of the
as performed on an Inveon PET/CT system, followed by a 10-min CT
Nguyen et al. EJNMMI Research 2013, 3:80 Page 13 of 16
http://www.ejnmmires.com/content/3/1/80over time, and the radioactivity clearance from the
systemic circulation (increasing tumour-to-blood con-
centration ratios) or from the muscle (increasing
tumour-to-muscle uptake ratios) over time. Bone up-
take of both radiotracers was low and has steadily de-
clined over time which indicates no significant in vivo
de-fluorination and subsequent fluoride bone uptake.
In the blocking study, we used only selective σ2 ligands
as competitors as the σ2 specificity of these radiotracers
had been previously established in naïve animals (manu-
script in preparation). The competing drugs (1 mg/kg in
100 μL) including haloperidol (Ki(σ2) = 20 nM) and un-
labelled SIG343 and SIG353 (Ki(σ2) = 8 and 2.7 nM, re-
spectively) were administered 5 min prior to radiotracer
injection. The concentration used deems to be in excess
for all compounds used (i.e. 532, 485 and 469 nM for
haloperidol, SIG343 and SIG353, respectively) which are
at least 50 times greater than the Ki values of the radio-
tracers for σ2 receptors to ensure a complete saturation
of receptor occupancy.
It is interesting to note that the uptake in the pancreas
were found to increase (↑55% to 89%, Ps < 0.001) in both
treatment groups (haloperidol-treated and unlabelled
SIG343-treated) compared to controls for 18F-SIG343.
However, this increased uptake phenomenon in the
pancreas was only observed in the unlabelled SIG353-
treated (↑37%, P < 0.001), but not in the haloperidol-
treated group, for 18F-SIG353 (P > 0.05). It is possible
that pancreas is a site of radioactive metabolite accu-
mulation, and the metabolism is a dynamic process
which would make it difficult to measure specific bind-
ing in this organ. This observation was also evident in,
and supported by, the biodistribution data which
showed that the uptake in the liver and pancreas was
constantly increasing over time. Although there was
no significant increase in radioactivity of the tracer in
the blood or bone as a result of the blocking drug
treatment (data not shown), based on the increased radio-
tracer uptake values over time in many organs expressing
σ receptors, we hypothesise that the continuing increase
in pancreas and liver uptake is likely due to an increase in
radioactive metabolites, rather than specific σ uptake.
Amongst the competing σ2 ligands, the pharmacokin-
etics of unlabelled SIG343 and SIG353 is unknown and
limited in rodent studies, particularly in mice for halo-
peridol, and the only available pharmacokinetic data of
haloperidol are those in rats [58] (terminal half-life of
1.5 h, intravenous bolus). Since haloperidol was reported
to have linear pharmacokinetics within the dose range
0.5 to 2.5 mg/kg [58], we chose the pre-administration
time for challenging the ligands for 5 min in the block-
ing studies. Haloperidol and the unlabelled SIG343/
SIG353 were able to block the uptake of the radiotracers
in organs of high concentrations of σ receptors innaïve animals (data not shown), especially in the case
of 18F-SIG343. This indicates the concentration and
the pre-administration time parameters of the com-
petitive ligands used in these experiments seemed to
be appropriate. However, the significant blocking of ra-
diotracer uptake by competing ligands was not ob-
served in the tumour for both radiotracers in the current
study. The discrepancy in the results of in vitro cell uptake
inhibition studies (in vitro specificity) and those of block-
ing studies (in vivo specificity) indicated that the pre-
administration time of 5 min for these challenging ligands
used in the current study may not be sufficient for the
drugs exerting their pharmacological action. This is highly
likely because in an in vitro system, the drugs have free ac-
cess to cell membrane receptors and are only limited by
their affinity, appropriate concentration used and the in-
trinsic efficacy. However, in an in vivo environment, in
addition to those parameters mentioned above, the drugs
are also limited by their pharmacokinetic properties before
they can reach the target for receptor occupancy or satur-
ation. In addition, the non-blocking of the competing
drugs observed in the tumour in the present study could
also be due to a number of variants such as the non-
specific binding of the tracers in the tumour, internalisa-
tion or internal localisation of surface receptor-ligand
complex in the tumour that was not readily blocked by
the competing σ ligands when the radiotracers were ad-
ministered. Other possibilities are pathophysiological sta-
tus of the tumour in the animal model used including
hypoxic fraction, proliferative or vasculature structure of
the tumour, or even the pathophysiology of the diseased
animals where the pharmacokinetics of both competing
drug and radiotracer could also be compromised.
Taken together, these factors could influence the ab-
sorption and distribution of competing drugs. There-
fore, while competing σ ligands showed high binding
affinity in the in vitro assay system, their pharmaco-
kinetics may not be able to reach a sufficiently high
concentration, or at a sufficient time, at the binding
sites in solid tumours to exert their competing effects
in our in vivo biodistribution study.
High amount of intact tracer in the tumour is desir-
able as it represents the stability of the radiotracer in the
target. Intact 18F-SIG343 and 18F-SIG353 were 80% and
65% in the tumour, respectively at 120 min, indicating a
moderate in vivo stability.
Unlike the biodistribution, PET imaging of 18F-SIG343
and 18F-SIG353 showed lower tumour uptake (0.9%ID/
cc and 1.3%ID/cc, respectively), resulting in low tumour-
to-background contrast which hampered the potential of
the radiotracers as tumour markers. PET images showed
high radioactive uptake in the abdominal cavity; hence,
high background activity which is consistent with the
biodistribution data where high uptake in the liver,
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The discrepancy in the results between in vivo PET and
ex vivo biodistribution studies may be attributed to sev-
eral reasons, including methodological differences in the
techniques employed or method quantification/analysis
of the images.
Firstly, methodological issues of data analysis should
be considered. The percentage of injected dose (%ID/g)
which is conventionally used in in vivo studies gives an
absolute index in binding which means that it reflects
specific and non-specific binding in targets (i.e. tumour
in this animal model), radioligand present in the sys-
temic blood circulation and possibly radioactive metabo-
lites in the tumour and blood circulation [59], as the
metabolisms of 18F-SIG343 and 18F-SIG353 have not
been fully assessed. However, results of the metabolite
studies indicated that the intact radiotracers were 65%
to 80% in the tumour; therefore, the fate of the remaining
fraction of the radiotracers cannot be fully concluded until
the metabolites are identified and quantified. The second
factor is the potential effect of inhalation anaesthesia used
in in vivo studies, but not in ex vivo studies, which may
also interfere with the kinetics of the radiotracer, especially
in terms of tissue equilibrium and the extent of tissue per-
fusion [60]. Finally, another factor is the difference in con-
centrations of the radioligand used, for instance, 1 MBq in
ex vivo studies compared with approximately 5 to 16 MBq
in PET studies. High radioactivity retention in the tail (ap-
proximately 20%ID/cc) observed for both radiotracers in-
dicated a misinjection possibility which could result in less
radiotracers available for the systemic circulation, hence
low radiotracer uptake in the target. Taken together, these
factors could contribute to the low uptake of the radio-
tracers in the tumour and to the discrepancy in results be-
tween ex vivo and in vivo studies.
Future studies using longer scans (>120 min) and longer
half-life radioisotopes compared to 18F and considering
that the amount of radiotracers in the tumour remained
constant, the issue of low tumour-to-background contrast
could be resolved.
Conclusions
The σ2 receptor is overexpressed in a variety of human
tumour cell lines and is a biomarker for tumour cell pro-
liferation, making it an attractive target for the develop-
ment of new radiotracers for tumour detection and
assessment of proliferative status using PET and SPECT
imaging. Two lead compounds from a series of novel
phthalimido compounds, SIG343 and SIG353, showing
high affinity and selectivity for the σ2 receptor in vitro
were selected for further development of the 18F-labelled
PET tracer. 18F-SIG343 and 18F-SIG353 were evaluated
in tumour-bearing mice, and their potential to image
the σ2 receptor in vivo was investigated. Biodistributionstudies showed high uptake and suitable kinetics of
both radiotracers in organs known to express σ recep-
tors. Relatively high tumour-to-blood and tumour-to-
muscle uptake ratios were observed for both 18F-SIG343
and 18F-SIG353. Furthermore, we were able to demon-
strate that 18F-SIG343 and 18F-SIG353 remained moder-
ately stable in vivo. However, blocking studies could not
fully confirm that the uptake of 18F-SIG343 and 18F-
SIG353 in the tumour was σ2-receptor-specific. PET im-
ages showed low tumour-to-background contrast and
high radioactivity localisation in the abdominal cavity for
both radiotracers making them less ideal candidates for
PET tumour imaging in the current animal model. Con-
tinuing the work in this direction, full potential of these
radiotracers will be revisited in more appropriate models
using different designed PET/SPECT protocols and
suitable radioisotopes of longer half-lives to address
the current low tumour-to-background contrast issue.
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